This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
AP2M1 / AP-2 complex subunit mu · IHC design guide
Design Immunohistochemistry for AP2M1
Plan AP2M1 paraffin-section IHC around the cytoplasmic staining reported in most tissues (HPA tissue IHC). This guide highlights control-tissue selection, fixation consistency and the uncertainty in the reported tissue staining (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
AP2M1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC); membrane and coated-pit association (UniProt) | |
| Staining pattern | Cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A06179-3) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Tissue staining reliability is uncertain (HPA tissue IHC) | |
| Regulation | Low tissue specificity (HPA tissue RNA) | |
| Isoform / epitope | 2 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended AP2M1 IHC & IF Protocols
The catalog antibody has a datasheet IHC-P protocol (datasheet: A06179-3). One published chromogenic AP2M1 IHC protocol is available for colorectal tissue (PMC10900655).
| Sample | Paraffin-embedded human kidney tissue; fixative not specified (datasheet A06179-3) |
| Fixation | Image fixative and duration unreported (datasheet A06179-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A06179-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A06179-3) |
| Primary antibody | Rabbit anti-AP2M1, 2-5 μg/ml (datasheet A06179-3) |
| Primary incubation | Overnight at 4 °C (datasheet A06179-3) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A06179-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | AP2M1-positive staining in glandular cells of appendix (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 for the catalog antibody (datasheet: A06179-3); the published colorectal protocol used high heat and pressure at pH 9.0 (PMC10900655).
Section 2
What Is the Expected AP2M1 Staining Pattern?
AP2M1 is an AP-2 adaptor associated with the cell membrane and coated pits; it has no transmembrane segment (UniProt Q96CW1). In paraffin-section IHC, expect mainly cytoplasmic staining in expressing cells, including neuronal and glandular cells (HPA: cytoplasmic expression in most tissues; medium in selected neuronal and glandular cells). Interpret modest signals cautiously because HPA rates tissue IHC reliability as Uncertain (HPA: Uncertain).
| Cytoplasmic staining in neuronal cells of the cerebral cortex or caudate, or in cerebellar granular-layer cells (HPA: Medium in each). | This matches reported tissue IHC. AP2M1 acts in membrane traffic at coated pits (UniProt Q96CW1), but a chromogenic cytoplasmic pattern need not resolve individual pits. Compare staining with the surrounding cells and a matched control; HPA calls the overall tissue pattern Uncertain (HPA: Uncertain). |
| Cytoplasmic staining in appendix, cervix, epididymis, or gallbladder glandular cells (HPA: Medium in each). | These are additional reported positive cell populations (HPA: Medium). Score the specified cells rather than treating every structure in the section as an expected positive. The HPA levels describe observed staining, not a guaranteed intensity for another antibody or laboratory (HPA: tissue IHC; HPA: Uncertain). |
| Predominantly nuclear staining, with little cytoplasmic signal, in an otherwise positive cell population. | A nuclear-dominant pattern conflicts with HPA tissue cytoplasmic staining and its supported ICC-IF plasma-membrane location (HPA: tissue IHC; HPA: subcellular). Treat it as a possible artefact or off-target signal and review controls and morphology before assigning AP2M1 positivity; the evidence does not establish nuclear localisation. |
| Strong staining in adipocytes or esophageal squamous epithelial cells (HPA: Not detected in these cells). | This differs from the reported tissue pattern and warrants checking cross-reactivity or endogenous chromogenic activity (HPA: tissue IHC; general IHC practice). Do not call a single stained cell definitive proof of either problem: HPA rates its tissue IHC reliability Uncertain, and the result may depend on the antibody (HPA: Uncertain). |
| Diffuse colour across cells, stroma, or an entire section, without a discernible cellular pattern. | Diffuse background cannot establish AP2M1 localisation; assess the no-primary control, blocking and detection steps (general IHC practice). A meaningful result should be interpretable in cells against their surroundings, with the cytoplasmic tissue pattern as the reference (HPA: tissue IHC). |
💡Expected AP2M1 appearanceCall a section positive when identifiable neuronal or glandular cells show interpretable cytoplasmic staining, with medium staining reported for the listed HPA examples; broad haze, nuclear-dominant colour, or strong signal in HPA-not-detected cells should prompt control review (HPA: tissue IHC; HPA: Uncertain; general IHC practice).
| Tissue and cell selection (HPA: tissue IHC). | HPA reports medium staining in selected neuronal and glandular populations, low staining in several other cell populations, and no detection in specified cells such as adipocytes (HPA: tissue IHC). Choose a reported positive population for an interpretive control, while allowing for the Uncertain reliability rating (HPA: Uncertain). |
| Compartment and membrane association (UniProt Q96CW1; HPA: subcellular). | AP2M1 associates with the cell membrane and coated pits without spanning the membrane (UniProt Q96CW1). HPA tissue IHC is described as cytoplasmic, whereas ICC-IF supports a plasma-membrane location (HPA: tissue IHC; HPA: subcellular). These observations guide interpretation at each method's resolution; they do not imply that every pit will be visible in IHC. |
| IHC antibody evidence (HPA: antibodies). | HPA lists antibody HPA036849 as Uncertain for IHC and HPA069870 as Supported for ICC, with no IHC status reported for HPA069870 (HPA: antibodies). Do not transfer an ICC validation label to paraffin-section IHC; interpret the catalog antibody against its own IHC controls (general IHC practice). |
| IF/ICC Q: What pattern is reported? (HPA: subcellular). | A: Plasma-membrane localisation is supported in ICC-IF images from MCF-7 and U-251MG (HPA: subcellular). That observation informs compartment comparison, but this IHC section gives no IF/ICC protocol or claim that its image validation establishes the IHC pattern (HPA: antibodies). |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in a reported medium-staining population, such as cerebral-cortex neuronal cells (HPA: Medium). | The run may have lost detectable signal, or this antibody and preparation may differ from HPA's observations; HPA tissue IHC reliability is Uncertain (HPA: Uncertain; general IHC practice). | Check a same-run reported positive control, primary-antibody and detection steps, and the selected cell population before concluding absence (HPA: tissue IHC; general IHC practice). |
| Colour appears in the no-primary control. | Primary-independent detection or endogenous activity can contribute to chromogenic staining (general IHC practice). | Review the detection and blocking controls, then compare the control with the tissue slide at the same exposure to the chromogen (general IHC practice). Do not score matching background as AP2M1. |
| Most structures show diffuse stain that obscures individual cells. | Excess background from staining or detection can prevent cell-level interpretation (general IHC practice). | Review blocking, washes, antibody concentration and chromogen development using matched controls (general IHC practice). Rescore only when the reported cytoplasmic pattern can be distinguished in cells (HPA: tissue IHC). |
| Signal is chiefly nuclear in a putative positive cell population. | This disagrees with the reported cytoplasmic tissue pattern and supported ICC-IF plasma-membrane localisation (HPA: tissue IHC; HPA: subcellular). | Verify cell boundaries and counterstain, inspect the no-primary control, and repeat with a validated IHC reagent if needed (general IHC practice). Keep the compartment discrepancy explicit when reporting the result. |
| Adipocytes or esophageal squamous epithelial cells stain strongly (HPA: Not detected). | Off-target binding or endogenous detection activity is possible; HPA's Uncertain tissue-IHC rating also limits a categorical negative call (HPA: tissue IHC; HPA: Uncertain; general IHC practice). | Compare a reported medium-staining cell population and the no-primary control in the same run, then assess whether the unexpected stain tracks tissue structures or background (HPA: tissue IHC; general IHC practice). |
| Only faint staining appears in a reported medium-staining cell population (HPA: tissue IHC). | HPA's level is an observed category, not a fixed intensity target for this antibody or run, and its tissue IHC reliability is Uncertain (HPA: tissue IHC; HPA: Uncertain). | Confirm that cells and controls are identifiable, review detection and antibody conditions, and score the observed compartment and cells rather than forcing a Medium grade (general IHC practice; HPA: tissue IHC). |
Experiment evidence
IHC & IF images showing AP2M1 staining
A06179-3 · IHCIHC analysis of AP2M1 using anti-AP2M1 antibody (A06179-3). AP2M1 was detected in a paraffin-embedded section of human kidney tissue. Heat m
A06179-3 · IFIF analysis of AP2M1 using anti-AP2M1 antibody (A06179-3). AP2M1 was detected in an immunocytochemical section of MCF-7 cells. Enzyme antige
A06179-1 · IHCImmunohistochemistry of AP2M1 in mouse kidney tissue with AP2M1 antibody at 2.5 μg/mL.
A06179-1 · IFImmunofluorescence of AP2M1 in Mouse Kidney cells with AP2M1 antibody at 20 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000161203-AP2M1/tissue/cerebral+cortex#imid_9610032
HPA · CerebellumHuman Protein Atlas IHC, Cerebellum. Source: https://www.proteinatlas.org/ENSG00000161203-AP2M1/tissue/cerebellum#imid_9610051
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000161203-AP2M1/tissue/colon#imid_9609974
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000161203-AP2M1/tissue/liver#imid_9609959
HPA · ICC-IF MCF-7Human Protein Atlas immunofluorescence, MCF-7, antibody HPA069870; green = AP2M1, blue = nucleus, red = microtubules.
HPA · ICC-IF MCF-7Human Protein Atlas immunofluorescence, MCF-7, antibody HPA069870; green = AP2M1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for AP2M1 IHC & IF
🧪Run cerebral cortex first: neuronal cells should show medium AP2M1 staining (HPA: cerebral cortex neuronal cells, Medium). Use esophageal squamous epithelial cells as a tissue negative (HPA: esophagus, Not detected); on the positive slide, judge staining in other cells against the no-primary background rather than assuming a named cell population is AP2M1-negative.
Positive control tissue: Appendix (Glandular cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show AP2M1 in MCF-7, U-251MG, with annotated localisation: Plasma membrane (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control, a concentration-matched rabbit isotype control matched to the antibody’s clonality, and AP2M1 knockout tissue or cells as a biological negative (selected-SKU caption: rabbit anti-AP2M1; standard IHC practice). Block endogenous peroxidase and assess background in the cortex section before interpreting DAB staining (standard chromogenic IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected-SKU paraffin-section caption does not state a fixative (selected-SKU tissue-IHC caption). The demonstrated workflow uses heat retrieval in EDTA, pH 8.0, but the evidence does not establish that retrieval is essential or that frozen sections or IF are easier (selected-SKU tissue-IHC caption). For cortical tissue, account for pigment and tissue background when scoring chromogenic signal (standard IHC practice); ICC-IF images in MCF-7 and U-251MG support plasma-membrane localization as an IF reference (HPA: subcellular).
HPA tissue IHC evidence for AP2M1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Caudate | Neuronal cells | Medium | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | Medium | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
| Oral mucosa | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
| Ovary | Ovarian stroma cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced AP2M1 IHC Tips
Troubleshoot AP2M1 staining in paraffin sections by checking retrieval, staining controls, cellular distribution and scoring against the available IHC evidence.
Which retrieval conditions should I start with for AP2M1 paraffin-section IHC?
Start with heat-mediated retrieval in EDTA at pH 8.0 for AP2M1 paraffin sections (datasheet A06179-3). The selected tissue image used this buffer before incubation with 2 μg/ml primary antibody overnight at 4°C (datasheet A06179-3). If signal is weak, check section adhesion, heating consistency and reagent coverage, then compare retrieval durations on adjacent sections (standard IHC practice). Keep antibody concentration and DAB development constant during that comparison so retrieval is the variable being assessed (standard IHC practice). The caption gives no heating duration, so record the duration used with each result (datasheet A06179-3).
Could fixation explain weak or inconsistent AP2M1 staining?
The selected paraffin-section caption does not state a fixative, and target-specific fixation sensitivity is unknown (datasheet A06179-3). Record the fixative, fixation duration and interval before processing for each specimen before comparing staining across batches (standard IHC practice). Compare suspect and reference sections using the same EDTA pH 8.0 retrieval and staining run (datasheet A06179-3; standard IHC practice). If morphology is poor as well as staining, review processing records and test an adjacent section before changing antibody conditions (standard IHC practice). Do not attribute a fixation effect to AP2M1 without a controlled comparison using the same specimen type (standard IHC practice).
Should AP2M1 appear at the membrane or throughout the cytoplasm?
AP2M1 is associated with the cell membrane and coated pits, while supported IF localisation is at the plasma membrane (UniProt Q96CW1 subcellular location; HPA subcellular). Tissue IHC reports cytoplasmic expression in most tissues, with uncertain staining reliability (HPA tissue IHC). Assess whether chromogenic signal follows cell outlines or occupies cytoplasm, and compare like cell types within the same section (standard IHC practice). AP-2 can disengage from endocytic sites before vesicle internalisation, so vesicle-like DAB dots alone do not establish an internalised AP2M1 pool (UniProt Q96CW1 subcellular location). Isolated nuclear staining warrants review against controls and morphology (standard IHC practice).
Can this antibody distinguish AP2M1 isoforms or phosphorylation states in tissue?
AP2M1 has 2 reported isoforms and an MHD region spanning residues 170–434 (UniProt Q96CW1 isoforms and domains). Phosphoserine at residue 45 and AAK1-dependent phosphothreonine at residue 156 are reported modifications (UniProt Q96CW1 modified residues). The supplied IHC caption does not identify the antibody epitope or establish isoform or phosphorylation selectivity (datasheet A06179-3). Check mapped immunogen information and sequence coverage before interpreting different staining patterns as isoform-specific (standard IHC practice). If modification dependence matters, use a separately validated modification-specific reagent and matched controls; routine DAB staining cannot establish that assignment (standard IHC practice).
How should I assess AP2M1 by multiplex IF alongside this IHC result?
Use the IF/ICC guide for its own protocol; the supplied product workflow documents paraffin-section chromogenic IHC (datasheet A06179-3). For a tissue comparison, pair AP2M1 with a marker identifying the expected cell type, such as neuronal cells in caudate, where tissue IHC reports medium staining (HPA tissue IHC; standard IF practice). Choose spectrally separated fluorophores after checking tissue autofluorescence and include single-color controls for bleed-through (standard IF practice). AP2M1 lacks a transmembrane segment, but the antibody epitope is unspecified; compare permeabilised and nonpermeabilised preparations before judging access to a cytosolic-facing epitope (UniProt Q96CW1 topology; datasheet A06179-3; standard IF practice).
How can I separate AP2M1 signal from chromogenic background?
The selected IHC image used a peroxidase-conjugated secondary antibody and DAB development, so inspect background in each detection step (datasheet A06179-3; standard IHC practice). Include a no-primary control and review endogenous peroxidase blocking, washes and DAB development time when diffuse brown signal appears (standard IHC practice). The caption reports 10% goat serum blocking and 2 μg/ml primary antibody overnight at 4°C (datasheet A06179-3). Compare any adjustment on adjacent sections while holding retrieval at EDTA pH 8.0 (datasheet A06179-3; standard IHC practice). Exclude pigment, folds and tissue edges from interpretation using morphology and controls (standard IHC practice).
What is a defensible way to score AP2M1 IHC across sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and tissue compartment before scoring, because tissue IHC describes broad cytoplasmic expression with uncertain reliability (HPA tissue IHC). Report the percentage of positive viable cells and an intensity-weighted H-score from 0–300, using fixed scoring thresholds across slides (standard IHC practice). If measuring stained area, report density per mm² of evaluable tissue and normalise to viable tissue area or the counted target-cell population (standard IHC practice). Keep retrieval, imaging and DAB development consistent, and blind scorers to group labels where feasible (standard IHC practice). Record excluded necrotic, folded or edge regions before comparing groups (standard IHC practice).
What findings make an AP2M1-positive stain convincing rather than artifactual?
Interpret staining alongside cell morphology and location: AP2M1 is linked to membrane-coated pits, while tissue IHC commonly reports cytoplasmic signal (UniProt Q96CW1 subcellular location; HPA tissue IHC). Compare the relevant cell population with adjacent cells and a no-primary control, rather than treating every brown deposit as AP2M1 (standard IHC practice). Isolated nuclear staining, edge-restricted staining, necrotic regions or signal reproduced in the no-primary control should prompt artefact review (standard IHC practice). Check endogenous peroxidase when brown signal persists without primary antibody in the DAB workflow (standard IHC practice). Treat apparent tissue negatives cautiously because HPA rates its tissue-IHC reliability uncertain (HPA tissue IHC).
Boster reagents
Best AP2M1 / AP-2 complex subunit mu IHC Antibodies
Two anti-AP2M1 antibodies have IHC images from paraffin sections of human or mouse kidney (catalog image captions); IF images show MCF-7 or mouse kidney cells (catalog IF image captions).
Real IHC data
Anti-AP2M1 Antibody ®
Cat # A06179-3
Real IHC data
Anti-AP-2 complex subunit mu AP2M1 Antibody
Cat # A06179-1
A06179-3 shows IHC in a human kidney paraffin section and IF in MCF-7 cells (A06179-3 image captions). A06179-1 shows IHC in mouse kidney tissue and IF in mouse kidney cells (A06179-1 image captions).
Which to pick: For human tissue IHC, choose A06179-3: its paraffin-section caption reports 2 μg/mL, EDTA retrieval at pH 8.0, and DAB detection; the fixative is unreported (A06179-3 IHC caption). For mouse tissue IHC, A06179-1 has a mouse kidney image at 2.5 μg/mL; its caption does not report section processing or fixative (A06179-1 IHC caption). For IF/ICC, A06179-3 lists both applications and shows IF in MCF-7 cells, while A06179-1 lists IF and shows mouse kidney cells; both list human, mouse, and rat reactivity, but their IHC images document only the species stated above (catalog applications, reactivity, and image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q96CW1 (AP2M1_HUMAN, AP-2 complex subunit mu).
- Human Protein Atlas. AP2M1 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. AP2M1 subcellular location (ICC-IF): Localized to the plasma membrane..
- Human Protein Atlas. AP2M1 antibody validation summary (2 antibodies).
- A multi-dimensional approach to unravel the intricacies of lactylation related signature for prognostic and therapeutic insight in colorectal cancer. Journal of translational medicine 2024 — PMC10900655.
- The role of AP2M1 in oncofetal characteristics: integrative in silico, in vitro, and in vivo analyses using zebrafish models. European journal of medical research 2025 — PMC12772027.
- Mendelian randomization analysis identifies HLA-A and AP2M1 as genetic biomarkers linked to immune-endocytic crosstalk in intervertebral disc degeneration. Journal of cell communication and signaling 2026 — PMC12906310.
- SNX10 enhances HCoV-OC43 infection by facilitating viral entry and inhibiting virus-triggered autophagy. Virologica Sinica 2025 — PMC12665429.
- PubMed PMID:7788527 — UniProt-cited evidence.
- PubMed PMID:16641997 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for AP2M1 (AP-2 complex subunit mu). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC); membrane and coated-pit association (UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A06179-3). Validated IHC antibody: A06179-3 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human kidney tissue; fixative not specified (datasheet A06179-3); 2. Fixation: Image fixative and duration unreported (datasheet A06179-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A06179-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A06179-3); 8. Primary antibody: Rabbit anti-AP2M1, 2-5 μg/ml (datasheet A06179-3); 9. Primary incubation: Overnight at 4 °C (datasheet A06179-3). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Tissue staining reliability is uncertain (HPA tissue IHC); Isoform / epitope: 2 isoforms ; epitope coverage is unspecified (UniProt); Regulation: Low tissue specificity (HPA tissue RNA). Evidence: UniProt Q96CW1, HPA tissue IHC · Uncertain, HPA ICC-IF · plasma membrane., Datasheet A06179-3, PMC10900655. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/AP2M1/immunohistochemistry-ihc-guide.